retatrutide ly3437943 glp-1 gip glucagon receptor agonist (LY3437943): Mechanism of Action and Research Overview Retatrutide the wonder drug: What's

Last month, Novo Nordisk won Food and Drug Administration approval for the first GLP-1 pill for weight loss

Olsen MB, Hovelmann U, Griffin J, Knudsen KM, Johansen T, Kendall D, et al

"In both age groups, the last dispensed prescription in 2023 was most commonly for injectable semaglutide [Ozempic] for Type 2 diabetes," Lee's group noted

Mehta LS, Velarde GP, Lewey J, Sharma G, Bond RM, Navas-Acien A, et al

Semaglutide was also the only GLP-1RA that effectively lowered the levels of low density lipoprotein (mean difference 0.16 mmol/L (95% confidence interval 0.30 to 0.02)

Given the results from recent studies, the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) recommend that patients with T2D and clinical cardiovascular disease (CVD) with inadequate glucose control despite treatment with metformin should receive an SGLT2 inhibitor or GLP-1 receptor agonist